Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Health Catalyst (HCAT) Research & Development (2018 - 2025)

Health Catalyst's Research & Development history spans 8 years, with the latest figure at $9.9 million for Q4 2025.

  • For Q4 2025, Research & Development fell 33.94% year-over-year to $9.9 million; the TTM value through Dec 2025 reached $49.8 million, down 14.12%, while the annual FY2025 figure was $49.8 million, 14.12% down from the prior year.
  • Research & Development reached $9.9 million in Q4 2025 per HCAT's latest filing, down from $12.3 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $20.8 million in Q3 2022 to a low of $9.9 million in Q4 2025.
  • Average Research & Development over 5 years is $15.9 million, with a median of $15.8 million recorded in 2021.
  • Peak YoY movement for Research & Development: rose 26.76% in 2022, then crashed 33.94% in 2025.
  • A 5-year view of Research & Development shows it stood at $17.5 million in 2021, then increased by 12.21% to $19.6 million in 2022, then rose by 3.44% to $20.3 million in 2023, then decreased by 26.05% to $15.0 million in 2024, then plummeted by 33.94% to $9.9 million in 2025.
  • Per Business Quant, the three most recent readings for HCAT's Research & Development are $9.9 million (Q4 2025), $12.3 million (Q3 2025), and $12.4 million (Q2 2025).